CVRdatabase
Menu

Allarity Therapeutics Europe ApS

Private limited companyCVR 34623562HørsholmActive

Allarity Therapeutics Europe ApS is a private limited company, based in Hørsholm, active in manufacture of pharmaceutical preparations, founded in 2012. Equity was negative at the end of 2025 (−DKK 216.6m). The company made a loss in both 2024 and 2025, most recently DKK 17.8m.

Follow
PDF reportCompare

Key figures · financial year 2025

Gross profit−DKK 39m+12.5% vs. 2024
Net profit−DKK 17.8m+95.5% vs. 2024
Equity−DKK 216.6m−9% vs. 2024
Employees4latest month from CVR

What has changed

calculated from recorded figures and dates

Financials: 2025 against 2024

  • The loss got smaller: from DKK 393.8m to DKK 17.8m (2024 → 2025).

Management and owners, last 24 months

  • New in management: Jeffrey Stuart Ervin (director, 04/07/2025).
  • Stepped down: Alexander Epshinsky (director, 04/07/2025).

Calculated from the latest two annual reports in sequence and from registrations in CVR. A figure that is missing in either year gives no line, and we derive no figures.

Financial statements

Financial years 2020–2025 · amounts in DKK thousand

Equity and net profit

−DKK 400m−DKK 300m−DKK 200m−DKK 100mDKK 0DKK 100mDKK 200mDKK 300mDKK 400m202020212022202320242025
EquityNet profit
Financial figures for Allarity Therapeutics Europe ApS
202020212022202320242025Change
Revenuenot statednot statednot statednot statednot statednot stated–
Gross profit−13,158−79,617−42,967−49,354−44,548−38,996+12.5%
Operating profit (EBIT)−16,910−79,974−170,425−55,811−396,790−46,703+88.2%
Profit before tax−20,907−43,654−173,647−54,278−411,690−23,293+94.3%
Net profit−18,557−76,279−142,438−48,735−393,818−17,793+95.5%
Total assets38,170498,792365,943362,23611,24925,806+129.4%
Equity−147,061386,284243,758195,023−198,795−216,588−9%
Liabilities185,23173,986109,770154,841210,044242,394+15.4%
Cash and cash equivalents10012,7172,3163025752,030+253%
Average number of employees–055440%

Source: annual reports filed with the Danish Business Authority (XBRL). Figures for the company (not the group); change is the latest year against the year before. “–” means the figure is not stated in the annual report. Revenue is not stated for 2020, 2021, 2022, 2023, 2024, 2025: smaller companies may omit it, and we do not derive it from other figures.

Download the figures as CSV · free with an account, amounts in whole DKK

−DKK 80m−DKK 60m−DKK 40m−DKK 20mDKK 0202020212022202320242025
Gross profitMedian, the industry (59 companies)

Signals from the financial statements

calculated from the 2025 figures

  • Negative equity

    Equity was −DKK 216.6m at the end of 2025.

    How is this calculated?

    Equity in the latest annual report is below zero.

  • Loss for 6 years in a row

    Net result has been negative in 2020–2025.

    How is this calculated?

    Net result is negative in the two or more latest annual reports in a row.

The signals are rules applied to the figures in the annual reports. They are not an assessment or credit rating of the company. See Data and method.

Annual reports

6 financial years
Annual reports for Allarity Therapeutics Europe ApS
Financial yearPeriodPublishedFigures forDocuments
202501/01/2025 – 31/12/202506/07/2026The companyPDF not statedXBRL
202401/01/2024 – 31/12/202403/07/2025The companyPDFXBRL
202301/01/2023 – 31/12/202328/06/2024The companyPDFXBRL
202201/01/2022 – 31/12/202202/07/2023The companyPDFXBRL
202101/01/2021 – 31/12/202127/07/2022The companyPDFXBRL
202001/01/2020 – 31/12/202005/07/2021The companyPDFXBRL

The figures from all the annual reports are shown on this page. The documents themselves (PDF and XBRL, the machine-readable edition) are downloaded with a Pro account: sign in or create a free account, and then choose Pro. XBRL is the edition the figures on the page are read from.

Employees

monthly figures from CVR
012345609/2310/2311/2312/2301/2402/2403/2404/2405/2406/2407/2408/2409/2410/2411/2412/2401/2502/2503/2504/2505/2506/2507/2508/2509/2510/2511/2512/2501/2602/2603/2604/2605/2606/2607/2608/26
Employees

Position in the industry

59 companies in the database

Comparison with the other companies in manufacture of pharmaceutical preparations based on the latest financial year.

Gross profit−DKK 39mNo. 52 of 57
Better than 9% of the companies in the industry
Equity−DKK 216.6mNo. 58 of 59
Better than 2% of the companies in the industry
Number of employees4No. 37 of 59
Better than 38% of the companies in the industry

Industry median: gross profit DKK 2.8m, net profit −DKK 2.2m, equity DKK 5.2m, 10 employees.

DKK 266kDKK 8.3mDKK 258mDKK 8bnDKK 79.6bn
Distribution of gross profit for 34 companies in the industry (latest financial year, logarithmic scale). Amber bar: where this company sits.

Compared with similar companies

size, age and company form
Rank among similar companies
GroupGross profitEquity
Companies with fewer than 20 employees69,967 companies in the comparison
No. 69,721of 69,742
Better than 0%
No. 69,955of 69,964
Better than 0%
Same industry and fewer than 20 employees37 companies in the comparison
No. 33of 36
Better than 9%
No. 36of 37
Better than 3%
Companies that are between 5 and 14 years old33,688 companies in the comparison
No. 33,569of 33,588
Better than 0%
No. 33,676of 33,687
Better than 0%
All companies of type ApS66,508 companies in the comparison
No. 66,358of 66,379
Better than 0%
No. 66,498of 66,505
Better than 0%

The rank is calculated among companies in the database with a figure for the latest financial year, and is shown only for groups of at least ten companies.

Compare with the industry

Manufacture of pharmaceutical preparations
Gross profit
  1. Allarity Therapeutics Europe ApS−DKK 39m
  2. Novo Nordisk A/SDKK 250.3bn
  3. H. Lundbeck A/SDKK 20.4bn
Net profit
  1. Allarity Therapeutics Europe ApS−DKK 17.8m
  2. Novo Nordisk A/SDKK 102.4bn
  3. H. Lundbeck A/SDKK 3.2bn
Equity
  1. Allarity Therapeutics Europe ApS−DKK 216.6m
  2. Novo Nordisk A/SDKK 194bn
  3. H. Lundbeck A/SDKK 24.9bn
Employees
  1. Allarity Therapeutics Europe ApS4
  2. Novo Nordisk A/S27,279
  3. H. Lundbeck A/S2,261

Latest financial year per company. Choose up to three companies from the largest in the industry.

Owners and group

from the Public Ownership Register
Owners
  • Allarity Acquisition Subsidiary, Inc.100%
Allarity Therapeutics Europe ApS

Management

2 active registrations

Executive management

Executive management at Allarity Therapeutics Europe ApS
NameRoleAppointed
Steen Meier KnudsenCEO12/12/2023
Jeffrey Stuart ErvinDirector04/07/2025
Founders
Buhl Krone Holding ApS
Former management (16)
Former management at Allarity Therapeutics Europe ApS
NameRoleAppointedResigned
Peter BuhlDirector01/08/201230/09/2019
Ulla Hald BuhlBoard member06/02/201511/12/2018
Jørgen Søberg PetersenBoard member06/02/201505/05/2015
Peter Birk RasmussenBoard member06/02/201511/12/2018
Duncan Charles McNaught MooreChair of the board06/02/201511/12/2018
Carani Balarman SanjeeviBoard member06/02/201511/12/2018
Steen Meier KnudsenBoard member05/05/201511/12/2018
Henrik Kristian MoltkeCEO30/09/201920/10/2020
Thomas Henrik JensenCEO20/10/202023/12/2021
Jens Erik KnudsenDirector23/12/202127/06/2022
Stefano Roberto CarchediCEO23/12/202129/06/2022
James G. CullemDirector01/02/202228/06/2022
James G. CullemCEO29/06/202212/12/2023
Joan Yvonne BrownDirector29/06/202212/09/2024
Steen Meier KnudsenDirector01/08/202211/12/2023
Alexander EpshinskyDirector12/09/202404/07/2025

Signing rule: Selskabet tegnes af 1 direktør

Address and production units

1 active production units

Venlighedsvej 1
2970 Hørsholm

Rudersdal Municipality · Postcode 2970

Other companies at the address (1)

  • Semantic ApSComputer consultancy and computer facilities management
Production units
Production unitAddressEmployeesP number
Allarity Therapeutics Europe ApSVenlighedsvej 1, 2970 Hørsholm41017836834

Purpose

Selskabets formål er at investere eller på anden måde være engageret i virksomheder, der beskæftiger sig med diagnostik og lægemiddeludvikling, herunder individualiseret medicin til kræftbehandling. Selskabet kan yde konsulent- og managementbistand til selskaber. The object of the company is to invest or otherwise be engaged in businesses that are involved in diagnostics and development of medicinal products, including individualized medicinal products for the treatment of cancer. The company may offer consultancy and management assistance to other companies.

The purpose is quoted from the register in Danish.

Changes year by year

65 registered events
20261 changeaccounts 1
  • Annual report for 2025 published
20253 changesmanagement 2 · accounts 1
  • Jeffrey Stuart Ervin appointed director
  • Alexander Epshinsky stepped down as director
  • Annual report for 2024 published
20243 changesmanagement 2 · accounts 1
  • Alexander Epshinsky appointed director
  • Joan Yvonne Brown stepped down as director
  • Annual report for 2023 published
20234 changesmanagement 3 · accounts 1
  • Steen Meier Knudsen appointed ceo
  • James G. Cullem stepped down as ceo
  • Steen Meier Knudsen stepped down as director
  • Annual report for 2022 published
20228 changesmanagement 7 · accounts 1
  • Steen Meier Knudsen appointed director
  • Annual report for 2021 published
  • Joan Yvonne Brown appointed director
  • James G. Cullem appointed ceo
  • Stefano Roberto Carchedi stepped down as ceo
  • James G. Cullem stepped down as director
  • Jens Erik Knudsen stepped down as director
  • James G. Cullem appointed director
20218 changesname 1 · management 3 · capital 1 · ownership 2 · accounts 1
  • Name changed from Oncology Venture Product Development ApS to Allarity Therapeutics Europe ApS
  • Jens Erik Knudsen appointed director
  • Stefano Roberto Carchedi appointed ceo
  • Thomas Henrik Jensen stepped down as ceo
  • Share capital changed from 2,196,593 DKK to 2,206,593 DKK
  • Allarity Acquisition Subsidiary, Inc. registered as owner (100%)
  • Allarity Therapeutics A/S is no longer registered as owner
  • Annual report for 2020 published
20202 changesmanagement 2
  • Thomas Henrik Jensen appointed ceo
  • Henrik Kristian Moltke stepped down as ceo
20192 changesmanagement 2
  • Henrik Kristian Moltke appointed ceo
  • Peter Buhl stepped down as director
20188 changesmanagement 5 · name 1 · ownership 2
  • Steen Meier Knudsen stepped down as board member
  • Peter Birk Rasmussen stepped down as board member
  • Carani Balarman Sanjeevi stepped down as board member
  • Ulla Hald Buhl stepped down as board member
  • Duncan Charles McNaught Moore stepped down as chair of the board
  • Name changed from ONCOLOGY VENTURE ApS to Oncology Venture Product Development ApS
  • Allarity Therapeutics A/S registered as owner (100%)
  • Oncology Venture Sweden AB is no longer registered as owner
201518 changesaddress 1 · ownership 8 · management 7 · capital 2
  • Moved to Venlighedsvej 1, 2970 Hørsholm
  • Oncology Venture Sweden AB registered as owner (100%)
  • SASS & LARSEN ApS is no longer registered as owner
  • Styrelsen for Forskning og Uddannelse is no longer registered as owner
  • TIMPCO NB ApS is no longer registered as owner
  • BUHL KRONE HOLDING ApS is no longer registered as owner
  • Allarity Therapeutics A/S is no longer registered as owner
  • Steen Meier Knudsen appointed board member
  • Jørgen Søberg Petersen stepped down as board member
  • Share capital changed from 1,597,546 DKK to 2,196,593 DKK
  • SASS & LARSEN ApS registered as owner (15%)
  • Share capital changed from 1,169,592 DKK to 1,597,546 DKK
  • Peter Birk Rasmussen appointed board member
  • Jørgen Søberg Petersen appointed board member
  • Carani Balarman Sanjeevi appointed board member
  • Ulla Hald Buhl appointed board member
  • Duncan Charles McNaught Moore appointed chair of the board
  • Styrelsen for Forskning og Uddannelse registered as owner (15%)
20135 changescapital 2 · ownership 3
  • Share capital changed from 1,052,632 DKK to 1,169,592 DKK
  • TIMPCO NB ApS registered as owner (5%)
  • Share capital changed from 125,000 DKK to 1,052,632 DKK
  • BUHL KRONE HOLDING ApS registered as owner (20%)
  • Allarity Therapeutics A/S registered as owner (20%)
20123 changesindustry 1 · founded 1 · management 1
  • Industry changed to Manufacture of pharmaceutical preparations (212000)
  • Registered as ONCOLOGY VENTURE ApS
  • Peter Buhl appointed director

Related companies

Same industry in Rudersdal

See all →

Same people in management

Largest in the industry

See all →

Source and updates

The information comes from the Danish Central Business Register (Danish Business Authority) and from annual reports filed with the Danish Business Authority. Last synchronised 24/10/2026.

View in CVRReport a correction